Detection of Urothelial Bladder Cancer Cells in Voided Urine Can Be Improved by a Combination of Cytology and Standardized Microsatellite Analysis

Peter J. Wild,1 Thomas Fuchs,3,4 Robert Steohr,5 Dieter Zimmermann,1 Simona Frigerio,1 Barbara Padberg,1 Inbal Steiner,6 Ellen C. Zwarthoff,6 Maximilian Burger,7 Stefan Denzinger,7 Ferdinand Hofstaedter,8,9 Glen Kristiansen,1 Thomas Hermanns,2 Hans-Helge Seifert,2 Maurizio Provenzano,2 Tullio Sulser,2 Volker Roth,10 Joachim M. Buhmann,3 Holger Moch,1 and Arndt Hartmann5

1Institute of Surgical Pathology and 2Department of Urology, University Hospital Zurich; 3Department of Computer Science and 4Competence Center for Systems Physiology and Metabolic Diseases, ETh Zurich, Zurich, Switzerland; 5Institute of Pathology, University of Regensburg; 6Central Tumor Registry Regensburg, Regensburg, Germany; 9Department of Pathology, Erasmus MC, Rotterdam, The Netherlands; Department of Urology and 10Computer Science Center for Systems Physiology and Metabolic Diseases, ETH Zurich, Zurich, Switzerland; 5Institute of Pathology, University of Erlangen, Department, University of Basel, Basel, Switzerland

Abstract

Purpose: To evaluate molecular and immunohistochemical markers to develop a molecular grading of urothelial bladder cancer and to test these markers in voided urine samples.

Experimental Design: 255 consecutive biopsies from primary bladder cancer patients were evaluated on a tissue microarray. The clinical parameters gender, age, adjacent carcinoma in situ, and multifocality were collected. Urovysion fluorescence in situ hybridization (FISH) was done. Expression of cytokeratin 20, MIB1, and TP53 was analyzed by immunohistochemistry. Fibroblast growth factor receptor 3 (FGFR3) status was studied by SNPshot mutation detection. Results were correlated with clinical outcome by Cox regression analysis. To assess the predictive power of different predictor subsets to detect high grade and tumor invasion, logistic regression models were learned. Additionally, voided urine samples of 119 patients were investigated. After cytologic examination, urine samples were matched with their biopsies and analyzed for loss of heterozygosity (LOH), FGFR3 mutation, polysomy, and p16 deletion using UroVysion FISH. Receiver operator characteristic curves for various predictor subsets were plotted.

Results: In biopsies, high grade and solid growth pattern were independent prognostic factors for overall survival. A model consisting of UroVysion FISH and FGFR3 status (FISH + FGFR3) predicted high grade significantly better compared with a recently proposed molecular grade (MIB1 + FGFR3). In voided urine, the combination of cytology with LOH analysis (CYTO + LOH) reached the highest diagnostic accuracy for the detection of bladder cancer cells and performed better than cytology alone (sensitivity of 88.2% and specificity of 97.1%).

Conclusions: The combination of cytology with LOH analysis could reduce unpleasant cystoscopies for bladder cancer patients. (Cancer Epidemiol Biomarkers Prev 2009;18(6):1798–806)

Introduction

At the time of first diagnosis, ~70% of bladder tumors are noninvasive papillary low-grade tumors (pT<sub>n</sub>). Despite the fact that the majority of urothelial bladder tumors are clinically benign, regular cystoscopic follow-up at intervals is done in all patients with non-muscle-invasive bladder cancer after complete transurethral resection to detect recurrence and progression.

Mutations of the tumor suppressor genes TP53 and RB1 are common and have predictive value in clinical studies of invasive bladder cancer (1-3). Although TP53 alterations have been suggested as prognostic marker in pTa tumors (4), the prognostic value of both TP53 and RB1 is restricted to invasive tumors. In non-muscle-invasive bladder cancer, homogeneous expression of cytokeratin 20 (CK20; ref. 5), lack of fibroblast growth factor receptor 3 (FGFR3) mutations (6, 7), and high nuclear Ki-67 labeling index (7) show promise in predicting recurrence. Mutations in the FGFR3 gene are very frequent in pTa bladder tumors (~75%; refs. 7-10). Hernandez et al. have determined the frequency and the prognostic value of FGFR3 mutations in patients with primary non-muscle-invasive bladder cancer in a large prospective study (n = 772; ref. 11). In analogy to the data presented by van Rhijn et al. (6), their findings strongly support the notion that FGFR3 mutations characterize a subgroup of bladder cancers with good prognosis. However, there is no prospectively evaluated set of molecular markers with sufficient predictive power to select patients for a differential therapeutic approach.

Conventional urine cytology is used as a complement to cystoscopy for the detection of new bladder carcinomas.
and recurrences. However, application of cystoscopy every 3 to 6 months is very unpleasant for the patient. In the past, the low sensitivity of urine cytology reported in diagnosing low-grade papillary tumors has limited its use and prevented cytology from replacing cystoscopy (12). Fluorescence in situ hybridization (FISH)-based detection systems are currently used in conjunction with cystoscopy for the examination of bladder washings and voided urine samples. The use of UroVysion Multicolor FISH (Vysis), a FISH assay for detection of bladder cancer, based on the use of voided urine samples, has been evaluated in multiple studies (13-15). The UroVysion FISH test was the first and only test approved by the U.S. Food and Drug Administration, which uses DNA probes to identify aneuploidy for chromosomes 3, 7, and 17 and loss of the 9p21 locus in urine specimens from subjects with urothelial bladder cancer. van Rhijn et al. (16) have systematically reviewed urine markers for bladder cancer surveillance. Urinary cytology afforded a median sensitivity of 35% (range, 13-75%), whereas the median sensitivity for FISH and microsatellite analysis was 79% (range, 70-86) and 82% (range, 75-92%). Microsatellite analysis of loss of heterozygosity (LOH) and FISH were among the most promising markers for surveillance (16). We and others have previously shown that the detection of bladder carcinoma cells can be improved by standardized microsatellite analysis (17, 18). Over 93% of patients with recurrent bladder cancer disease were identified by a combination of microsatellite (LOH) analyses and cytology of their voided urine samples.

High histologic grade as a marker for chromosomal instability is the clinically most important marker for increased risk of progression to muscle-invasive disease. However, histologic grading has a high interobserver variability with varying prognostic implications (19).

The aim of the current study was to systematically evaluate a set of molecular and immunohistochemical markers to (a) develop a reliable molecular grading of urothelial bladder cancer and (b) evaluate the usefulness of these markers to detect bladder cancer cells in voided urine.

Materials and Methods

Bladder Cancer Tissue Microarray. A tissue microarray was constructed as described previously (10) from 255 consecutive, formalin-fixed, paraffin-embedded, primary urothelial bladder cancer tissues (Institute of Pathology, University of Regensburg). Clinical data were obtained from the Central Tumour Registry Regensburg and by telephone interviews (M.B. and S.D.) in case of missing data. The tissue microarray contained two tissue cores of each tumor specimen. The Institutional Review Board of the University of Regensburg approved analysis of tissues from human subjects. H&E-stained slides of all tumors were evaluated by a single surgical pathologist (A.H.). Tumor stage and grade were assigned according to International Union Against Cancer and WHO criteria (20). Invasive bladder carcinomas were graded as either low grade (G2) or high grade (G3). Growth pattern was determined for all invasive tumors (≥pT1). Papillary growth was defined by the presence of a papillary tumor component (≥20%) with a histologic grade identical to the invasive tumor. All other tumors were considered to have a solid growth pattern. Clinicopathologic data are summarized in Supplementary Table S1. Retrospective clinical follow-up data were available regarding the endpoints recurrence-free and overall survival. The median follow-up period was 77 months (range, 0-166 months). Thirty-eight

| Table 1. Polysomy and relative p16 deletion in relation to clinicopathologic, molecular, and immunohistochemical markers |
| --- |
| **Variable** |
| **Categorization** |
| **Polysoy** |
| ≤18% | >18% | P* |
| **Relative p16 deletion** |
| ≤14% | >14% | P* |
| **Clinicopathologic data** |
| Tumor stage |
| pTa | 62 | 75 | <0.001 |
| pT1 | 5 | 17 | 27 |
| pT2 | 4 | 66 | 20 |
| pT3 | 0 | 2 | 2 |
| pT4 | 0 | 2 | 2 |
| **Histologic grade** |
| Low | 64 | 76 | <0.001 |
| High | 7 | 89 | 35 |
| **Adjacent carcinoma in situ** |
| No | 69 | 139 | 0.004 |
| Yes | 2 | 26 | 16 |
| **Multifocality** |
| Solitary | 12 | 39 | 0.032 |
| Multifocal | 59 | 126 | 112 |
| **Growth pattern** |
| Papillary | 69 | 124 | <0.001 |
| Solid | 2 | 40 | 14 |
| **Molecular data** |
| FGFR3 gene |
| Wild-type | 12 | 88 | <0.001 |
| Mutation | 44 | 49 | 60 |
| **Immunohistochemistry** |
| MIB1 immunohistochemistry |
| ≤25% | 62 | 100 | <0.001 |
| >25% | 7 | 57 | 28 |
| TP53 immunohistochemistry |
| ≤10% | 64 | 103 | <0.001 |
| >10% | 3 | 59 | 23 |
| CK20 immunohistochemistry |
| Superficial staining pattern | 22 | 25 | 0.013 |
| Negative or >10% | 49 | 134 | 35 |

*Boldface representing P values < 0.05.
of 215 (15%) analyzable patients died during follow-up. The median follow-up for censored patients was 84 months. Recurrences were defined as cystoscopically visible tumors (using photodynamic diagnosis with 5-aminolevulinic acid) with histologic verification.

**Urine Samples.** As described previously (17), voided urine samples of 119 patients scheduled for transurethral resection were prospectively collected over a period of 20 months and matched with their corresponding biopsies. Of these, 81 biopsies proved to be neoplastic on histologic examination. Characteristics are given in Supplementary Table S2. Additional 38 urine samples were collected from patients whose biopsies turned out to be histologically normal or displayed inflamed urothelium without presence of neoplastic cells. Half of these tumor-negative samples were derived from patients without previous history of bladder cancer. All urine samples (15 mL) were directly collected at the Department of Urology, University Hospital Zurich, shortly before transurethral resection. The urine samples were centrifuged at 1,300 × g for 10 min and sediments were immediately processed for cytologic examination and FISH analysis. This study has been approved by the local ethics committee (StV-14/2003; July 30, 2003) and informed consent was obtained from all patients.

**Cytologic Examination of Urine Sediments.** Urine sediments were resuspended in PBS and one to three cytospin slides were prepared from an aliquot. The slides were fixed with Cytostat 400 solution (Simat) and stained with standard Papanicolaou. A cell density between 25 and 50 cells per visual field using a ×20 objective was regarded as sufficient for analysis. Slides were reviewed in a blinded fashion by a cytopathologist (B.P.) and classified according to the following morphologic criteria: cells with severe atypia diagnostic of neoplasia (P), moderately atypical cells suspicious of neoplasia (S), cells with reactive alterations (NR), and cells with normal morphology (N).

**Immunohistochemistry.** Immunohistochemical studies were done as described previously (10) One surgical pathologist (A.H.) performed a blinded evaluation of the slides. Positive TP53 immunoreactivity was defined as strong nuclear staining in >10% of the tumor cells. The percentage of MIB1-positive cells of each specimen was determined as described previously (21). High MIB1 labeling index was defined if >25% of the tumor cells were positive (7). CK20 staining was defined as normal (superficial staining pattern) or abnormal (negative or >10% stained) according to Harnden et al. (5).

**DNA Isolation.** Genomic DNA of paraffin-embedded tumors on the tissue microarray was isolated from 1.5 mm punch biopsies of the paraffin blocks (one tissue core per case). Tumor areas were marked by a surgical pathologist (A.H.) to ensure a tumor cell content of at least 80%. DNA isolation was done using the Magna Pure DNA isolation kit (Roche) according to the manufacturer’s instructions. DNA from urine samples was extracted and purified with a DNA Blood Mini-Kit (Qiagen) following instructions of the manufacturer. For the few samples containing only little DNA, at least 2 ng DNA was applied.

**FGFR3 Mutation Analysis.** FGFR3 mutation analysis was done using the SNaPshot method (22). All mutations were verified by a second and independent SNaPshot analysis.

| Variable                  | Categorization | Tumor recurrence | Overall survival |
|---------------------------|----------------|------------------|------------------|
| Pathologic data           |                |                  |                  |
| Tumor stage               | pTa            | 146 72 0.7534    | 146 4 <0.001    |
|                           | pT1            | 48 18 48         | 3                |
|                           | pT2            | 56 15 56         | 27               |
|                           | pT3            | 56 15 56         | 27               |
|                           | pT4            | 3 1 2            | 2                |
| Histologic grade          |                |                  |                  |
| Low                       | 150 49 0.176   | 150 5 <0.001    |
| High                      | 105 32 105     | 105 33          |
| Adjacent carcinoma in situ| No             | 222 95 0.6429   | 222 26 0.0001   |
|                           | Yes            | 33 11 33        | 12               |
| Multifocality             |                |                  |                  |
| Unifocal tumor            | 53 19 0.7129   | 53 14           |
| Multifocal tumor          | 202 87 202     | 202 24          |
| Growth pattern            |                |                  |                  |
| Papillary                 | 207 95 0.3254  | 207 13          |
| Solid                     | 47 10 47       | 24              |
| Immunohistochemistry      |                |                  |                  |
| MIB1 ≤25%                 | 168 76 0.7484  | 168 13          |
| >25%                      | 68 23 68       | 68 24           |
| TP53                      | ≤10%           | 179 80 0.5483   | 179 22           |
| >10%                      | 66 22 66       | 66 16           |
| CK20                      |                |                  |                  |
| Superficial staining pattern ≤14% | 49 23 0.6335 | 49 2 0.0155 |
| Negative or >10%          | 192 74 192     | 192 35          |
| Molecular data            |                |                  |                  |
| FGFR3 mutational status   | Wild-type      | 110 38 0.1382   | 110 24 0.0026   |
|                           | Mutation       | 98 50 98        | 7                |
| Relative p16 deletion     | ≤14%           | 128 56 0.881    | 128 12 0.009    |
|                           | >14%           | 108 40 108      | 108 22           |
| Polysomy                  | ≤18%           | 71 31 0.958     | 71 3 0.004     |
|                           | >18%           | 165 65          | 165 31          |

*Only the initial biopsy of each patient is included.
†Log-rank test (two-sided); boldface representing P values < 0.05.
Table 3. Multivariate analysis of factors possibly influencing overall survival (n = 186)

| Variable                  | Categorization | Global P  | Reverse selection (limit P = 0.1) |
|---------------------------|----------------|-----------|-----------------------------------|
| Pathologic data           |                |           | Hazard ratio (95% confidence interval) |
| Tumor stage               | PTx            | 0.558     | —                                  |
|                           | PT1,4          | 1         |                                    |
| Histologic grade          | Low            | 0.199     | 6.608 (1.929-22.633) 0.003         |
|                           | High           | 1         |                                    |
| Adjacent carcinoma in situ| No             | 0.516     | —                                  |
|                           | Yes            | 1         |                                    |
| Multifocality             | Unifocal tumor | 0.304     | —                                  |
|                           | Multifocal tumor| 1        |                                    |
| Growth pattern            | Papillary      | 0.002*    | 4.804 (1.959-11.783) 0.001         |
|                           | Solid          | 1         |                                    |
| MIB1 immunohistochemistry | ≤25%           | 0.823     | —                                  |
|                           | >25%           | 1         |                                    |
| TP53 immunohistochemistry | ≤10%           | 0.106     | 0.488 (0.213-1.114) 0.088          |
|                           | >10%           | 1         |                                    |
| FGFR3 gene                | Wild-type      | 0.199     | —                                  |
|                           | Mutation       | 1         |                                    |
| CK20 immunohistochemistry | Superficial     | 0.585     | —                                  |
|                           | staining pattern|         |                                    |
|                           | Negative or >10%|         |                                    |
| Relative p16 deletion     | ≤14%           | 0.945     | —                                  |
|                           | >14%           | 1         |                                    |
| Polysomy                  | ≤18%           | 0.918     | —                                  |
|                           | >18%           | 1         |                                    |

*Boldface representing P values < 0.05.

**FISH Analysis of Paraffin Specimens.** Multicolor FISH was done using the UroVysion probe set (Abbott Laboratories) according to the manufacturer's instructions to assess aberrations of chromosomes 3, 7, and 17 by centromeric probes and to detect relative deletions of p16 on locus 9p21 (23). For each case, 50 nuclei were selected for scoring according to morphologic criteria using 4',6-diamidino-2-phenylindole staining. Only nonoverlapping intact nuclei were scored. Clearly distinguishable nonurothelial cells were disregarded. All hybridizations were evaluated by two investigators (R.S. and I.S.) with random quality control checks (A.H.). Each cell was simultaneously analyzed for centromeric signals of chromosomes 3, 7, and 17 and the p16 locus on 9p21. A cell was considered aberrant if at least one of three centromeric signals was amplified (>2 signals per cell) or if 9p21 was deleted. Polyploid cells (4 signals of all the three probes) were regarded normal (euploid). A relative deletion of the p16 locus (CDKN2A) was recognized if the signal number of 9p21 was >1 unit lower than the mean value of the centromeric signals. Based on the occurrence of polysomy and deletions of 9p21 in non-tumor-associated bladder urothelium of patients with benign prostatic hyperplasia (n = 10), a cutoff was defined using three times the SD (23). Accordingly, a case was considered aberrant if ≥9 cells of 50 showed polysomy (>18% of the cells). A sample was considered carrying a deletion of p16 if >7 of 50 cells (>14% of the cells) showed a relative deletion of 9p21.

**FISH Analysis of Voided Urine Samples.** In each case, 25 selected cells were analyzed. The cell selection criteria included patchy and lighter nuclear 4',6-diamidino-2-phenylindole staining, nuclear enlargement, irregular nuclear contour, and presence in a small cluster. Overlapping cells were not analyzed. Samples were scored as FISH positive, if ≥4 cells showed at least 3 copies of any of the centromeric signals for chromosomes 3, 7, and 17 and if ≥12 cells displayed a homozygous loss of 9p21 (17). Due to technical reasons, only 2 of the 38 (5%) nonneoplastic urine samples were analyzable with FISH.

**Statistical Analysis.** Statistical analyses were completed using SPSS version 16.0 (SPSS) and R (24). Differences were considered significant if P < 0.05. All samples were considered independent.

Associations between measured parameters were obtained by applying χ² and two-sided Fisher's exact tests. The Kaplan-Meier method was used to compare curves for the different variables with regard to recurrence-free and overall survival, with significance evaluated by two-sided log-rank statistics. For the analysis of recurrence-free survival, patients were censored at the date when cystectomy was done or at the time of their last tumor-free clinical follow-up appointment. For survival analysis, patients were censored at the time of their last clinical follow-up appointment. Cox proportional hazard ratios were estimated to obtain risks of death and to find independent prognostic factors in a multivariate model. Limit for reverse selection procedures was P = 0.1.

To assess the predictive power of different predictor subsets, a logistic regression model was learned for each set. Cross-validation was used to validate the predictive power of the models. Therefore, 70% of the samples were drawn at random to form the training set on which a model was learned, which then was tested on the 30% of bag samples. This procedure was repeated 100 times for each model to get estimates for the prediction error. Student's t test was employed to quantify differences between the error distributions of different models. Data from voided urine samples were described by plotting receiver operator characteristic (ROC) curves of the posterior probability for various predictor subsets. The best operation point was highlighted and the corresponding sensitivity, specificity, and positive and negative predictive values (PV+, PV-) were reported.
Results

Tissue Microarray Study of Urinary Bladder Cancer. Immunohistochemical and Molecular Markers. The prognostic effect of the UroVysion kit in concert with four previously described molecular markers (FGFR3, CK20, MIB1, and TP53) was investigated retrospectively. Investigation of UroVysion FISH in a series of 255 primary urothelial bladder cancers using tissue microarray technology was informative in 92.5% (236 of 255) of the cases. Cases of noninterpretable results were due to poor technical quality or lack of epithelial cell content. Polysomy of at least one chromosome was found in 69.9% (165 of 236) and a relative deletion of 9p21 in 45.8%.

![Figure 1](image_url)

**Figure 1.** A to D, analysis of the prediction performance of the three models based on noninvasive predictors (CLINICAL, FISH, and FISH + FGFR3) and the two models based on invasive predictors (molecular grade and immunohistochemistry). The box plots show the area under the ROC curve to predict high histologic grade (A and B) and infiltrative growth (stage ≥pT1; C and D) based on 100 cross-validation experiments. Corresponding ROC curves for the three models based on noninvasive predictors (CLINICAL, FISH, and FISH + FGFR3) and the two models based on invasive predictors (molecular grade and immunohistochemistry). The ROC curves plotted are generated by varying the threshold of the logistic regression model \( \log(p(x)/(1-p(x))) = b_0 + \sum_{k=1}^{k} b_k x_k \) and are the average curves based on 100 cross-validation experiments.
(108 of 236) of urothelial neoplasms. Results of FGFR3 mutation analysis and MIB1, TP53, and CK20 immunohistochemistry have been published previously (10) and are given in Supplementary Tables 1 and 3.

Table 1 shows the association of UroVysion FISH results with clinicopathologic, immunohistochemical, and molecular parameters. Polysomy and relative p16 deletion was significantly associated with high tumor stage, high grade, and solid growth pattern. Almost all cases with adjacent carcinoma in situ showed polysomy in at least one chromosome (P = 0.004). These data confirm that polysomy and relative p16 deletions are associated with adverse histopathologic characteristics. Interestingly, a relative p16 deletion was predominantly found in solitary compared with multifocal urothelial bladder tumors (P < 0.001). As expected, polysomy and relative p16 deletion were significantly associated with wild-type FGFR3 status, high proliferation, high TP53 immunoreactivity, and abnormal CK20 staining pattern (Table 1).

**Model Comparison.** Given the prognostic effect of histologic grade, sensitivity and specificity for the detection of high-grade tumors were calculated. In this study, we compared five different models for their power to predict the surrogate markers high grade and infiltrative tumor growth (stage ≥pT1) using a logistic regression model. The first model consisted of the clinical parameters sex, age, adjacent carcinoma in situ, and multifocality (CLINICAL). The second model comprised polysomy and relative p16 deletion (FISH). The third model extends the FISH model for the FGFR3 mutational status (FISH + FGFR3). The latter two models were constructed with markers, which could also be measured noninvasively using urine. The fourth model was the molecular grading model from van Rhijn et al. (7) and consisted of MIB1 immunohistochemistry and FGFR3 mutational status (molecular grade). The last model consisted of the immunohistochemical markers MIB1, TP53, and the CK20 pattern.

Targeting high tumor grade, the (noninvasive) FISH + FGFR3 model performs slightly better (P = 0.001) than the molecular grading model from van Rhijn et al. (7) with respect to the area under curve (AUC). Both have an AUC of ~0.9 as shown in Fig. 1A and B. Observing the ROC curves in Fig. 1B in detail, it can be seen that on average FISH + FGFR3 is more sensitive and that van Rhijn et al. molecular grading is more specific regarding high grade. The classic immunohistochemical markers were superior to FISH + FGFR3 (P < 0.001) and the molecular grade (P < 0.001). The clinical markers alone (CLINICAL) perform worse than all other discussed models. FISH analysis alone failed only in 4 of 96 high-grade bladder cancer cases (3 pT1 and 1 pT2 tumor). All other high-grade tumors were FISH positive.

Targeting infiltrative tumor growth (stage ≥pT1), the FISH + FGFR3 model and the molecular grading model performed equally well with respect to the AUC (0.9; Fig. 1C and D). Again, classic immunohistochemistry markers are superior to FISH + FGFR3 and the molecular grade.

Our results show that a model consisting of UroVysion FISH and FGFR3 status (FISH + FGFR3) can predict high
grade just as well as the molecular grade proposed by van Rhijn et al. (7) and feature a higher sensitivity. Although a model based on the classic immunohistochemical markers is still the most powerful regarding the target high tumor grade, our FISH + FGFR3 model reaches nearly the same accuracy (0.9 versus 0.95 AUC) only with markers that could be measured with noninvasive techniques using urine samples instead of paraffin-embedded specimens. Parameters and P values of the FISH + FGFR3 logistic regression model are given in Supplementary Table S4. The model contained polysomy, relative p16 deletion, and FGFR3 mutational status as predictors from which polysomy and FGFR3 status are significant for the prediction of high grade.

**Voided Urine Study.** An independent set of 119 voided urine samples were investigated to estimate the diagnostic power of the different assays. After cytologic examination, voided urine samples were matched with corresponding biopsies and analyzed for LOH, FGFR3 mutation, polysomy, and relative p16 deletion using Ur-oVysion FISH. A mutated FGFR3 gene was found significantly more frequent in patients with malignant disease (P = 0.005; Table 4). Only one patient with a normal biopsy was found to have a urine specimen with mutated FGFR3. Of note is that the same patient developed a pTa G2 bladder tumor with mutated FGFR3 within the same year of follow-up. Mutated FGFR3 was significantly associated with a positive cytologic result (P < 0.001; Table 4). None of the cytologically negative cases displayed a FGFR3 mutation. Separate results of the analysis of voided urine samples for patients with high-grade (n = 40) and low-grade (n = 41) bladder tumors are given in Supplementary Table S5.

Sensitivity, specificity, and positive and negative predictive values for the detection of bladder cancer cells in voided urine were calculated (Fig. 2A-F). Six different models were investigated for their power to predict bladder cancer cells in urine. The three methods (CYTO, LOH, and FGFR3) were tested individually (Fig. 2A-C). Additionally, FGFR3 and LOH analysis were tested in combination with cytology (CYTO + FGFR3, and CYTO + LOH). Targeting neoplastic cells, the combination of cytology with LOH and FGFR3 analysis performed equally well, respectively. Observing the ROC curves in Fig. 2D and E in detail, it can be seen that on average CYTO + FGFR3 is slightly more sensitive and CYTO + LOH is more specific for the detection of bladder cancer cells.

**Figure 2.** A to F, ROC curves for six different models to predict bladder cancer cells in a set of prospectively collected voided urine samples. The three methods (CYTO, LOH, and FGFR3) were tested individually for their ability to detect bladder cancer cells in urine (A–C). Additionally, FGFR3 and LOH analysis were tested in combination with cytology (D and E). The combination of the three techniques (CYTO + LOH + FGFR3) did not add significant diagnostic advantage (F).
The combination of the three techniques (CYTO + LOH + FGFR3) did not add significant diagnostic advantage (Fig. 2F) when compared with the dual models. Results of the FISH assay could not be included in the logistic regression analysis for cancer cell detection because only 2 of the 38 (5%) nonneoplastic urine samples were analyzable with FISH. Sixty-nine percent of the urine samples from patients with a malignant bladder biopsy were UroVysion FISH positive. Measures of the performance of the various assays for the detection of high-grade versus non-high-grade tumors are provided in Supplementary Fig. S1A to F.

Discussion

In this study, we show that the combination of classic cytology with LOH analysis reaches the highest diagnostic accuracy for the detection of urothelial bladder cancer cells in voided urine samples.

To analyze large numbers of bladder cancer specimens, we first evaluated a tissue microarray comprising 255 consecutive primary bladder cancers. In our survival study, solid growth pattern and high histologic grade were the most important prognostic factor for overall survival. However, histologic grading has a high interobserver variability with varying prognostic implications (19). Burger et al. (25) have shown that the current WHO classification (20) reflects the outcome of bladder cancer patients more accurately than the 1973 classification system (26). The authors concluded that novel methods including molecular markers need to be evaluated for clinical use. In a second study on urothelial bladder cancer from the same group (n = 221), Burger et al. (25) prospectively investigated the prognostic value of the WHO 1973 and 2004 grading systems and biomarkers FGFR3, CK20, and Ki-67. They found that both grading systems contribute valuable independent information. Interestingly, combining WHO 2004 grading with FGFR3 status allowed a better risk stratification for patients with high-grade non-muscle-invasive urothelial bladder cancer.

A set of molecular and immunohistochemical markers was evaluated to develop a reliable and objective grading systems of urothelial bladder cancer. A model consisting of UroVysion FISH and FGFR3 status (FISH + FGFR3) predicted high grade significantly better compared with the molecular grade proposed by van Rhijn et al. (ref. 7; Fig. 1A and B).

In general, urethrocystoscopy (every 3–4 months for the first 2 years and longer intervals in subsequent years) remains the standard of care for the detection and follow-up of urothelial bladder cancer. Interestingly, van der Aa et al. (27) have assessed the discomfort and pain reported during follow-up of patients (n = 220) with non-muscle-invasive low-grade urothelial bladder cancer comparing urethrocystoscopy and surveillance by microsatellite analysis. According to van der Aa et al., periodic urethrocystoscopy caused pain and discomfort in about a third of patients, whereas the burden of microsatellite analysis appeared fully attributable to the waiting time for the test result. The authors concluded that less invasive surveillance tests are urgently needed (27).

But can the results of our aforementioned tissue microarray study be used for the detection of neoplastic cells in voided urine? To address this question, we estimated the diagnostic power for the detection of bladder cancer cells in 119 voided urine samples using LOH and FGFR3 analysis, UroVysion FISH, and cytology as predictors. We could show that the combination of classic cytology with LOH analysis (CYTO + LOH) significantly increased the accuracy to detect malignant urothelial cells in voided urine (Fig. 2E). In our study, sensitivity and specificity of conventional cytology was already 88.2% and 79.4% (AUC = 0.894; Fig. 2A). Using a combination of cytology and FGFR3 analysis (CYTO + FGFR3), sensitivity and specificity could not be increased (Fig. 2D). The combination of cytology with microsatellite analysis (CYTO + LOH) was able to increase specificity (97.1%) and the area under the ROC curve (Fig. 2D). However, sensitivity slightly decreased to 79.4%. Combination of the three techniques (CYTO + LOH + FGFR3) did not add significant diagnostic advantage (Fig. 2F).

These results are contrary to data published by van Rhijn et al. (28) who have also combined LOH and FGFR3 mutation analysis (molecular grade) for the detection of urothelial cancer cells in voided urine. After cytologic examination, an independent set of voided urine samples was matched with corresponding biopsies and analyzed for LOH, FGFR3 mutation, polysomy, and p16 deletion using UroVysion FISH. Combining results of LOH and FGFR3 mutation analysis, the sensitivity of the combined approach increased to 89% and was superior to the sensitivity of conventional cytology for every clinical subdivision (28). In our study, however, sensitivity and specificity of conventional cytology were already very high (88.2% and 79.4%). The area under the ROC curve in Fig. 2A (AUC 0.894) could only be increased by adding the results of the microsatellite analysis (AUC 0.936; Fig. 2E).

Recently, van der Aa et al. (18) have reported the results of a longitudinal prospective multicenter trial for surveillance of patients with low-grade non-muscle-invasive urothelial cancer using microsatellite analysis (n = 228). The authors concluded that microsatellite analysis on voided urine samples is not sufficiently sensitive to recommend implementation in routine clinical practice.

Classic cytology is still regarded as an important adjunct to urethrocystoscopy. Cytologic examination of voided urine is cheap, established in almost every pathology department, and should be part of any bladder cancer surveillance protocol. However, application of urine cytology is operator-dependent and can be hampered by the low sensitivity for low-grade lesions (29). In contrast to our study, simultaneous cytologic examinations were not taken into account by van der Aa et al. when calculating sensitivity and specificity of the various tests (18, 28).

The combination of cytology with LOH analysis reached the highest diagnostic accuracy for the detection of urothelial bladder cancer cells in voided urine samples. A monitoring scheme alternating invasive cystoscopy with a combination of noninvasive techniques (including classic urine cytology and LOH analysis) could reduce unpleasant interventions and improve follow-up compliance of patients with recurrent urothelial bladder cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
Acknowledgments

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Monika Kerscher, Nina Nießl, Anne Pietryga-Krieger, and Rudolf Jung for excellent technical assistance and Armin Pauer (Central Tumour Registry, Regensburg) for help in obtaining the clinical data.

References

1. Cordon-Cardo C, Zhang ZE, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217–21.
2. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090–4.
3. Masters JR, Vani UD, Grigor KM, et al. Can p53 staining be used to identify patients with aggressive superficial bladder cancer. J Pathol 2003;200:74–81.
4. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53–9.
5. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 1999;353:974–7.
6. van Rhijn BW, Lurkin I, Radvanyi F, Kikels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) muta-
tion is a strong indicator of superficial bladder cancer with low recur-
rence rate. Cancer Res 2001;61:1265–8.
7. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and 
MB-1 is superior to pathologic grade for the prediction of clinical out-
come. J Clin Oncol 2003;21:1912–21.
8. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mu-
tations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 
2001;158:1955–9.
9. van Rhijn BW, Montironi R, Zwarthoff EC, Jobis AC, van der Kwast 
TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002; 
198:245–51.
10. van Oers JM, Wild PJ, Burger M, et al. FGFR3 mutations and a normal 
CK20 staining pattern define low-grade non-invasive urothelial blad-
tumours. Eur Urol 2007;52:760–6.
11. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of 
FGFR3 mutations as a prognostic factor in nonmuscle invasive urothe-

dial bladder carcinomas. J Clin Oncol 2006;24:3664–71.
12. Brown FM. Urine cytology. It is still the gold standard for screening. 
Urol Clin North Am 2000;27:25–37.
13. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Clinical utility of a 
multiprobe FISH assay in voided urine specimens for the detection of 
bladder cancer and its recurrences, compared with urinary cytology. 
Eur Urol 2002;42:547–52.
14. Halling KC, King W, Sokolova IA, et al. A comparison of cytology and 
fluorescence in situ hybridization for the detection of urothelial carci-

noma. J Urol 2000;164:1768–75.
15. Bubendorf L, Grillo B, Sauter G, Miithatsch MJ, Gasser TC, Dalquen P. 
Multiprobe FISH for enhanced detection of bladder cancer in voided 
urine specimens and bladder washings. Am J Clin Pathol 2001;116:
79–86.
16. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for 
bladder cancer surveillance: a systematic review. Eur Urol 2005;47:
736–48.
17. Frigerio S, Padberg BC, Strebel RT, et al. Improved detection of blad-
ner carcinoma cells in voided urine by microsatellite analysis. Int J 
Cancer 2007;121:329–38.
18. van der Aa MN, Zwarthoff EC, Steyerberg EW, et al. Microsatellite anal-
ysis of voided-urine samples for surveillance of low-grade non-muscle-

invasive urothelial carcinoma: feasibility and clinical utility in a pro-
spective multicenter Study (Cost-Effectiveness of Follow-up of Urinary 
Bladder Cancer Trial [CEFUB]). Eur Urol. 2008 May 15. [Epub ahead of 
print].
19. Tosoni I, Wagner U, Sauter G, et al. Clinical significance of interob-
server differences in the staging and grading of superficial bladder 
cancer. BJU Int 2000;85:48–53.
20. Ehle JN, Sauter G, Epstein JJ, Sesterhenn I, editors. World Health Or-
organization classification of tumours. Pathology and genetics of tu-
mours of the urinary system and male genital organs. Lyon: IARC 
Press; 2004.
21. Nocito A, Bubendorf L, Maria Tinner E, et al. Microarrays of bladder 
cancer tissue are highly representative of proliferation index and his-
tological grade. J Pathol 2001;194:549–57.
22. van Oers M, Lurkin I, van Exsel AJ, et al. A simple and fast method for 
the simultaneous detection of nine fibroblast growth factor recep-
tor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 
2005;11:7743–8.
23. Schwarz S, Rechenmacher M, Filbeck T, et al. Value of multicolor Flu-
orescence in situ hybridization (UroVysion-TM) in the differential diag-
nosis of flat urothelial lesions. J Clin Pathol 2008;61:272–7.
24. Ihaka R, Gentleman R. A: a language for data analysis and graphics. J 
Comput Graph Stat 1996;5:299–314.
25. Burger M, Denzinger S, Wieland WE, Stief CG, Hartmann A, Zaak D. 
Does the current World Health Organization classification predict the 
outcome better in patients with noninvasive bladder cancer of early or 
regular onset. BJU Int 2008;102:194–7.
26. Mostofi FK, Sorbin LH, Torloni H. Histological typing of urinary blad-
der tumours. International classification of tumours. Vol. 19. Geneva: 
WHO; 1973.
27. van der Aa MN, Steyerberg EW, Sen FE, et al. Patients’ perceived bur-
den of cystoscopic and urinary surveillance of bladder cancer: a ran-

domized comparison. BJU Int 2008;101:1106–10.
28. van Rhijn BW, Lurkin I, Chopin DK, et al. Combined microsatellite and 
FGFR3 mutation analysis enables a highly sensitive detection of urother-

dial cell carcinoma in voided urine. Clin Cancer Res 2003;9:257–63.
29. Sherman AB, Koss LG, Adams SE. Interobserver and intraobserver di-

ferences in the diagnosis of urothelial cells. Comparison with clas-
sification by computer. Anal Quant Cytol 1984;6:112–20.
Correction: Detection of Urothelial Bladder Cancer Cells in Voided Urine can be Improved by a Combination of Cytology and Standardized Microsatellite Analysis

In this article (1), which was published in the June 2009 issue of *Cancer Epidemiology, Biomarkers & Prevention*, data regarding relative p16 deletion in Table 1 and regarding overall survival in Table 2 were partly displaced. The correct tables are shown on the next page.

### Table 1. Polysomy and relative p16 deletion in relation to clinically-pathologic, molecular and immunohistochemical markers

| Variable                  | Categorisation | Polysomy | Relative p16 deletion |
|---------------------------|----------------|----------|-----------------------|
|                           |                | ≤18%     | >18% | P* | ≤14% | >14% | P* |
| Clinico-pathologic data:  |                |          |      |    |      |      |    |
| Tumour stage              |                |          |      |    |      |      |    |
| pTa                       | 62             | 75       | <0.001 |    | 90   | 47   | <0.001 |
| pT1                       | 5              | 39       | 17    | 27  |      |      |    |
| pT2                       | 4              | 46       | 20    | 30  |      |      |    |
| pT3                       | 0              | 2        | 0     | 2   |      |      |    |
| pT4                       | 0              | 3        | 1     | 2   |      |      |    |
| Histologic grade          |                |          |      |    |      |      |    |
| low grade                 | 64             | 76       | <0.001 |    | 93   | 47   | <0.001 |
| high grade                | 7              | 89       | 35    | 61  |      |      |    |
| Adjacent carcinoma in situ|                |          |      |    |      |      |    |
| no                        | 69             | 139      | 0.004 | 116 | 92   | 0.228 |
| yes                       | 2              | 26       | 12    | 16  |      |      |    |
| Multifocality             |                |          |      |    |      |      |    |
| solitary                  | 12             | 39       | 0.302 | 16  | 35   | <0.001 |
| multifocal                | 59             | 126      | 112   | 73  |      |      |    |
| Growth pattern            |                |          |      |    |      |      |    |
| papillary                 | 69             | 124      | <0.001 | 114 | 79   | 0.003 |
| solid                     | 2              | 40       | 14    | 28  |      |      |    |
| Molecular data:           |                |          |      |    |      |      |    |
| FGFR3 gene                |                |          |      |    |      |      |    |
| wild-type                 | 12             | 88       | <0.001 | 46  | 54   | 0.014 |
| mutation                  | 44             | 49       | 60    | 33  |      |      |    |
| Immunohistochemistry:     |                |          |      |    |      |      |    |
| MIB1 IHC                  |                |          |      |    |      |      |    |
| ≤25%                      | 62             | 100      | <0.001 | 94  | 68   | 0.056 |
| >25%                      | 7              | 57       | 28    | 36  |      |      |    |
| TP53 IHC                  |                |          |      |    |      |      |    |
| ≤10%                      | 64             | 103      | <0.001 | 101 | 66   | 0.002 |
| >10%                      | 4              | 59       | 23    | 40  |      |      |    |
| CK20 IHC                  |                |          |      |    |      |      |    |
| superficial staining pattern |            |          |      |    |      |      |    |
| negative or >10%          | 22             | 25       | 0.013 | 35  | 12   | 0.002 |

*Bold face representing P-values <0.05.*
Table 2. Univariate analyses of factors possibly influencing recurrence-free and overall survival

| Variable                  | Categorisation | Tumor recurrence | Overall survival |
|---------------------------|----------------|------------------|------------------|
|                           |                | n*   | events | p* | n*   | events | p† |
| Pathologic data:         |                |      |        |    |      |        |    |
| Tumour stage             |                |      |        |    |      |        |    |
| pTa                       |                | 146  | 72     | 0.7534 | 146  | 4    | <0.0001 |
| pT1                       |                | 48   | 18     | 0.7534 | 48   | 3    | <0.0001 |
| pT2                       |                | 56   | 15     | 0.7534 | 56   | 27   | <0.0001 |
| pT3                       |                | 2    | 1      | 0.7534 | 2    | 2    | <0.0001 |
| pT4                       |                | 3    | 0      | 0.7534 | 3    | 2    | <0.0001 |
| Histologic grade         |                |      |        |    |      |        |    |
| low grade                 |                | 150  | 49     | 0.176  | 150  | 5    | <0.0001 |
| high grade                |                | 105  | 32     | 0.176  | 105  | 33   | <0.0001 |
| Adjacent carcinoma in situ|                |      |        |    |      |        |    |
| no                        |                | 222  | 95     | 0.6429 | 222  | 26   | <0.0001 |
| yes                       |                | 33   | 11     | 0.6429 | 33   | 12   | <0.0001 |
| Multifocality             |                |      |        |    |      |        |    |
| unifocal tumor            |                | 53   | 19     | 0.7129 | 53   | 14   | 0.0029 |
| multifocal tumor          |                | 202  | 87     | 0.7129 | 202  | 24   | 0.0029 |
| Growth pattern            |                |      |        |    |      |        |    |
| papillary                 |                | 207  | 95     | 0.3254 | 207  | 13   | <0.0001 |
| solid                     |                | 47   | 10     | 0.3254 | 47   | 24   | <0.0001 |
| Immunohistochemistry:     |                |      |        |    |      |        |    |
| MIB1                      |                |      |        |    |      |        |    |
| ≤25%                      |                | 168  | 76     | 0.7484 | 168  | 13   | <0.0001 |
| >25%                      |                | 68   | 23     | 0.7484 | 68   | 24   | <0.0001 |
| TP53                      |                |      |        |    |      |        |    |
| ≤10%                      |                | 179  | 80     | 0.5483 | 179  | 22   | 0.0161 |
| >10%                      |                | 66   | 22     | 0.5483 | 66   | 16   | 0.0161 |
| CK20                      |                |      |        |    |      |        |    |
| superficial staining pattern|            | 49   | 23     | 0.6535 | 49   | 2    | 0.0155 |
| negative or >10%          |                | 192  | 74     | 0.6535 | 192  | 35   | 0.0155 |
| Molecular data:           |                |      |        |    |      |        |    |
| FGFR3 mutational status   |                |      |        |    |      |        |    |
| wild type                 |                | 110  | 38     | 0.1382 | 110  | 24   | 0.0026 |
| mutation                  |                | 98   | 50     | 0.1382 | 98   | 7    | 0.0026 |
| Relative p16 deletion     |                |      |        |    |      |        |    |
| ≤14%                      |                | 128  | 56     | 0.881  | 128  | 12   | 0.009  |
| >14%                      |                | 108  | 40     | 0.881  | 108  | 22   | 0.009  |
| Polysomy                  |                |      |        |    |      |        |    |
| ≤18%                      |                | 71   | 31     | 0.958  | 71   | 3    | 0.004  |
| >18%                      |                | 165  | 65     | 0.958  | 165  | 31   | 0.004  |

*Only the initial biopsy of each patient is included.
†Log Rank test (2-sided); bold face representing P-values <0.05.

Reference
1. Wild PJ, Fuchs T, Stoehr R, Zimmermann D, Frigerio S, Padberg B, Steiner I, Zwarthoff EC, Burger M, Denzinger S, Hofstaedter F, Kristiansen G, Hermanns T, Sefert HH, Provenzano M, Sulser T, Roth V, Buhrman JM, Moch H, Hartmann A. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev 2009;18:1798–806.

©2010 American Association for Cancer Research.
doi: 10.1158/1055-9965.EPI-10-0005
Detection of Urothelial Bladder Cancer Cells in Voided Urine Can Be Improved by a Combination of Cytology and Standardized Microsatellite Analysis

Peter J. Wild, Thomas Fuchs, Robert Stoehr, et al.

Cancer Epidemiol Biomarkers Prev 2009;18:1798-1806.

Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/18/6/1798

Supplementary Material
Access the most recent supplemental material at:
http://cebp.aacrjournals.org/content/suppl/2009/05/18/1055-9965.EPI-09-0099.DC1

Cited articles
This article cites 26 articles, 8 of which you can access for free at:
http://cebp.aacrjournals.org/content/18/6/1798.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/18/6/1798.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cebp.aacrjournals.org/content/18/6/1798.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.